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OBJECTIVE—Little is known concerning the primary cause(s)
of mortality in type 1 diabetes responsible for the excess
mortality seen in this population.
RESEARCH DESIGN AND METHODS—The Allegheny
County (Pennsylvania) childhood-onset (age 18 years) type 1
diabetes registry (n  1,075) with diagnosis from 1965 to 1979
was used to explore patterns in cause-speciﬁc mortality. Cause of
death was determined by a mortality classiﬁcation committee of
at least three physician epidemiologists, based on the death
certiﬁcate and additional records surrounding the death.
RESULTS—Vital status for 1,043 (97%) participants was ascer-
tained as of 1 January 2008, revealing 279 (26.0%) deaths overall
(141 females and 138 males). Within the ﬁrst 10 years after
diagnosis, the leading cause of death was acute diabetes compli-
cations (73.6%), while during the next 10 years, deaths were
nearly evenly attributed to acute (15%), cardiovascular (22%),
renal (20%), or infectious (18%) causes. After 20 years’ duration,
chronic diabetes complications (cardiovascular, renal, or infec-
tious) accounted for 70% of all deaths, with cardiovascular
disease as the leading cause of death (40%). Women (P  0.05)
and African Americans (P  0.001) have signiﬁcantly higher
diabetes-related mortality rates than men and Caucasians, re-
spectively. Standardized mortality ratios (SMRs) for non–diabe-
tes-related causes do not signiﬁcantly differ from the general
population (violent deaths: SMR 1.2, 95% CI 0.6–1.8; cancer: SMR
1.2, 0.5–2.0).
CONCLUSIONS—The excess mortality seen in type 1 diabetes
is almost entirely related to diabetes and its comorbidities but
varies by duration of diabetes and particularly affects women and
African Americans. Diabetes 59:3216–3222, 2010
M
ortality rates for type 1 diabetes are much
higher than in the general population in the
U.S. and worldwide (1–3). Understanding the
primary cause(s) of this excess mortality is
essential for developing interventions to decrease mortal-
ity rates in type 1 diabetes. This excess mortality has been
attributed both to acute diabetes complications as well as
to chronic diabetic renal and cardiovascular disease
(CVD). Previous reports have shown that renal disease is
the principal cause of mortality in the ﬁrst 20 years of type
1 diabetes; subsequently, CVD predominates (4–6).
Only a handful of recent reports address cause-speciﬁc
mortality in population-based type 1 diabetes cohorts
(7–12) and even fewer have long-term follow-up (15
years) (10,11). A recent Norwegian 20-year follow-up
report addressed long-term cause-speciﬁc mortality in
1,906 individuals with childhood-onset type 1 diabetes
(standardized mortality ratio [SMR]  4.0) (11) and found
that, before age 30 years, acute complications was the
leading cause of death in this cohort, whereas, after age 30
years, CVD was predominant, consistent with ﬁndings
from the large Diabetes U.K. Study (12). The Diabetes U.K.
Study classiﬁed type 1 diabetes as insulin treatment before
age 30 years (n  23,752), and based on death certiﬁcate
data alone, found that acute metabolic complications
predominated before age 30 years, but again thereafter,
CVD becomes the leading cause. Aside from the current
study, the Norwegian study is the only other long-term
type 1 diabetes study to investigate deaths using available
clinical data in addition to death certiﬁcate data.
Findings from the Pittsburgh Epidemiology of Diabetes
Complications (EDC) study suggest that the incidence of
end-stage renal disease has declined quite markedly,
whereas the incidence of coronary artery disease remains
relatively unchanged over 30 years in individuals with type
1 diabetes (13). This is of particular interest, since renal
disease is thought to be the major driver of CVD in type 1
diabetes (14).
Herein, we explore cause-speciﬁc mortality trends by
sex, race, and calendar year of diagnosis to determine how
type 1 diabetes mortality is changing over time using a
large population-based type 1 diabetes cohort in Allegheny
County (Pittsburgh), Pennsylvania (diagnosis 1965–1979).
Apart from a race-speciﬁc analysis where this cohort was
combined with the Pittsburgh EDC study, cause-speciﬁc
mortality has not been formally evaluated in this popula-
tion since 1985 (15). We speciﬁcally examine whether the
percentage of renal-related cardiovascular deaths is
changing over time as well as other cause-speciﬁc
patterns.
RESEARCH DESIGN AND METHODS
Study population. The Allegheny County Type 1 Diabetes Registry (n 
1,075) has been described in detail (16) and consists of all individuals
diagnosed with childhood-onset (age 18 years) type 1 diabetes in Allegheny
County between 1 January 1965 and 31 December 1979 and placed on insulin
at diagnosis. Individuals were identiﬁed via hospital record review and
validated by contacting pediatricians throughout the county (ascertainment
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ﬁbrosis, Down’s syndrome, or steroid-induced diabetes) were excluded. This
cohort was part of a comparative international study (Diabetes Epidemiology
Research International [DERI]) of type 1 diabetes mortality rates (18).
To determine the vital status as of 1 January 2008, all participants were
contacted initially by letter, then by telephone if necessary, to complete a brief
health update questionnaire. The study protocol was approved by the Univer-
sity of Pittsburgh Institutional Review Board.
Mortality classiﬁcation procedures. Deaths were identiﬁed by 1) partici-
pant contact, 2) the Social Security Death Index, or 3) the National Death
Index and then conﬁrmed by death certiﬁcate. Attempts were made to obtain
the following information, when appropriate: 1) medical records surrounding
the death, 2) autopsy/coroner’s reports, and 3) interview with next-of-kin
regarding the circumstances surrounding the death. Protocols for abstracting
standardized data from these records have been comprehensively detailed
(15). A Mortality Classiﬁcation Committee (MCC) consisting of three or more
physician epidemiologists used standardized protocols to determine 1) the
underlying cause of death and 2) the ordered contribution of all other causes
of death. Internal adjudication (A.M.S. and T.J.O.) has been made for all
deaths not yet ﬁnalized by the MCC (n  60) based on the same protocols.
Causes of death were grouped as shown in Table 1.
Statistical analysis. Each individual’s contribution to person-years of fol-
low-up was calculated from date of diabetes diagnosis to either 1 January 2008
or date of death or date lost to follow-up. To compare continuous variables
between groups, Student t test and one-way ANOVA were used, adjusting for
multiple comparisons using the Bonferroni correction. The 
2 or Fisher’s
exact test was used to compare categorical variables between groups, as
appropriate. To evaluate temporal trends in cause-speciﬁc mortality, calendar
year at diagnosis was categorized into three groups (1965–1969, 1970–1974,
and 1975–1979). Also, causes of death were grouped into four broad catego-
ries for some analyses (Table 1): 1) acute diabetes-related causes, 2) chronic
diabetes-related causes (including the renal, cardiovascular, infection, and
other diabetes categories), 3) non-diabetes causes (including accident or
suicide, cancer, and other non-diabetes categories), and 4) unknown cause.
Cause-speciﬁc mortality rates were calculated by dividing the number of
deaths by the person-years of follow-up for individuals at risk during the
speciﬁed duration interval. Cause-speciﬁc expected mortality was estimated
using the person-years method based on general population life tables for
Allegheny County, Pennsylvania, or when deaths from a particular cause were
extremely rare in the age-matched county population (i.e., renal deaths and
infections), based on life tables for the state of Pennsylvania (19). Cause-
speciﬁc SMRs adjusting for age, sex, and race were calculated as the observed
divided by the expected number of deaths in each age, sex, and race category,
and 95% CIs were determined with the Poisson distribution. Cause-speciﬁc
mortality rates and SMRs were compared using rate ratio analyses (20).
Statistical signiﬁcance of P  0.05 was used. Analyses were performed using
SPSS 17.0 (SPSS, Chicago, IL).
RESULTS
Demographic characteristics of the Allegheny County
Type 1 Diabetes Registry cohort are presented by year of
diabetes diagnosis in Table 2. Vital status was conﬁrmed
as of 1 January 2008 for 1,043 participants (97.0% ascer-
tainment rate). A total of 279 deaths (26.0%) occurred in
this population over 34,363 total person-years of follow-up.
Nearly half of the total deaths occurred in the 1965–1969
diagnosis cohort (n  132), with signiﬁcantly fewer deaths
in the 1970–1974 and 1975–1979 diagnosis cohorts (n  92
and 55, respectively). No signiﬁcant sex or racial differ-
ences existed by diagnosis cohort; however, age at onset
signiﬁcantly increased across diagnosis cohorts (P 
0.01).
Proportions of deaths by cause. Figure 1 shows the
proportions of deaths by underlying cause for 10-year
intervals of diabetes duration. Within the ﬁrst 10 years of
diabetes onset, 70% of all deaths were due to acute
diabetes complications. After 10 years of diabetes, acute
complications become a minor but persistent (9–15%)
cause of death in this population. Also, after 10 years of
diabetes, CVD becomes the leading cause of death, even-
tually accounting for 40% of all deaths after 20 years’
duration.
By separating these data by sex, race, and diabetes
duration, some patterns emerge (see supplemental Fig. 1,
available in an online appendix at http://diabetes.
diabetesjournals.org/cgi/content/full/db10-0862/DC1). In
females, diabetes complications caused 90% of all deaths
in the ﬁrst 30 years after diagnosis compared with 75% of
TABLE 1
Cause-of-death groups for classiﬁcation by the MCC
Diabetes-related
Acute diabetic complications: diabetic ketoacidosis,
hyperglycemia, hypoglycemia, hypokalemia, and diabetic
coma unspeciﬁed
Diabetic renal disease: diabetic nephropathy, end-stage renal
disease, and dialysis-related complications
Cardiovascular: coronary artery disease, myocardial
infarction, sudden cardiac death, cerebrovascular disease,
peripheral vascular disease, heart failure, arrhythmias, and
cardiomyopathy
Infection: pneumonia, bronchitis, sepsis, meningitis,
encephalitis, osteomyelitis, mycosis, and endocarditis
Other diabetes: autonomic neuropathy, angiopathy,
uncontrolled diabetes, and post-transplant complications
Non–diabetes-related
Cancer: any form of cancer
Accident or suicide: violent deaths, motor vehicle crashes,
alcohol/drug overdose, and other accidental deaths
(drowning, fall, ﬁre)
Other non-diabetes: other causes not speciﬁc to diabetes,
e.g., sickle cell trait, bulimia/anorexia, lupus, septic
abortion, epilepsy, multiple sclerosis, gastric ulcer, or HIV
Unknown, where cause of death could not be determined
TABLE 2
Demographic characteristics of Allegheny County Type 1 Diabetes Registry population by diagnosis cohort as of 1 January 2008
Diagnosis cohort
Overall 1965–1969 1970–1974 1975–1979
n 355 391 329 1,075
Vital status conﬁrmed 96.6 (343) 97.4 (381) 97.0 (319) 97.0 (1,043)
Deceased 37.2 (132) 23.5 (92) 16.7 (55)* 26.0 (279)
Male 50.4 (179) 54.5 (213) 50.5 (166) 51.9 (558)
Caucasian 92.4 (328) 93.6 (366) 91.8 (302) 92.7 (996)
Age at diabetes diagnosis 10.5  4.4 10.8  4.0 11.4  4.0* 10.9  4.2
Mean diabetes duration† 34.6  9.0 32.2  7.3 28.9  4.7* 32.0  7.6
Mean age† 45.1  9.2 42.9  7.8 40.3  5.9* 42.9  8.0
Person-years of follow-up 12,277.6 12,584.8 9,500.7 34,363.1
Data are % (n) or means  SD. *P  0.01 for either 
2 or ANOVA across diagnosis cohort groups. †Type 1 diabetes duration and age at death
or last follow-up.
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from one death of unknown cause, all deaths in African
American participants were due to either acute or chronic
diabetes complications, whereas nearly 20% of all deaths
in Caucasian participants were not related to diabetes.
However, only eight deaths occurred in African Americans
in the ﬁrst 20 years of diabetes, limiting further stratiﬁca-
tion by year of diagnosis.
Cause-speciﬁc mortality rates. Cause-speciﬁc mortality
rates were stratiﬁed by sex and race (Table 3), as well as
by year of diabetes diagnosis (Table 4). Overall, females
with type 1 diabetes had a higher mortality rate for
diabetes-related deaths (female:male [F:M] mortality rate
ratio [RR]  1.3, P  0.05), whereas males tended to have
a higher mortality rate from non–diabetes-related causes
(M:F RR 1.9, P  0.06). These ﬁndings remained signiﬁcant
when deaths not yet ﬁnalized by the MCC (n  60) were
excluded from analysis. Of the 16 total deaths caused by
accident or suicide, 14 occurred in males (M:F RR 7.2, P 
0.009). When the mortality rates were stratiﬁed by both
sex and duration of diabetes (data not shown), the only
signiﬁcant difference was that within the ﬁrst 10 years
after diagnosis, 12 of 14 acute complication deaths oc-
curred in women (F:M RR 6.6, P  0.01).
When stratiﬁed by race, the overall mortality rate was
signiﬁcantly higher in African American participants (RR 2.5,
P  0.001, Table 3). Speciﬁcally, African American partici-
pants with type 1 diabetes died of diabetes complications at
much higher rates than Caucasian participants: acute: RR 4.8,
P  0.001; renal disease: RR 4.6, P  0.001; CVD: RR 1.9, P 
0.05; and infection: RR 2.8, P  0.01. All comparisons by race
remained signiﬁcant after excluding deaths not yet ﬁnalized
by the MCC except for CVD (RR 1.4, P  0.48). Conversely,
all deaths from non–diabetes-related causes occurred in
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FIG. 1. Distribution of underlying causes of death within 10-year intervals of type 1 diabetes duration. Ten deaths where the cause of death was
unknown were excluded.
TABLE 3
Cause-speciﬁc mortality rates by sex and race in the Allegheny County Type 1 Diabetes Registry cohort
n*
Sex Race
Male
(n  138)
Female
(n  141)
Caucasian
(n  239)
African American
(n  40)
Diabetes-related 239 613.9 (499.7–728.1) 786.2 (650.0–922.4)† 618.0 (532.1–703.8) 1,851.3 (1,277.6–2,425.1)†
Acute complication 45 105.1 (57.8–152.3) 159.7 (98.3–221.1) 102.5 (67.5–137.4) 555.4 (241.2–869.6)†
Renal disease 37 88.5 (45.1–131.8) 129.0 (73.8–184.2) 86.9 (54.7–119.2) 416.6 (144.4–688.7)†
CVD 101 276.5 (199.9–353.2) 313.3 (227.3–399.2) 276.4 (219.0–333.8) 555.4 (241.2–869.6)†
Infection/other 56 143.8 (88.5–199.1) 184.3 (118.3–250.2) 152.2 (109.6–194.8) 324.0 (84.0–564.0)
Non–diabetes–related 40 149.3 (93.0–205.6) 79.8 (36.4–123.3) 124.2 (85.7–162.7) 0.0
Accident/violent 16 77.4 (36.9–118.0) 12.3 (0.0–29.3)† 49.7 (25.3–74.0) 0.0
Cancer 10 27.7 (3.4–51.9) 30.7 (3.8–57.6) 31.1 (11.8–50.3) 0.0
Other 14 44.2 (13.6–74.9) 36.9 (7.4–66.3) 43.5 (20.7–66.2) 0.0
Overall 279 763.2 (635.8–890.5) 866.1 (723.1–1,009.0) 742.2 (648.1–836.3) 1,851.3 (1,277.6–2,425.1)‡
Data are n or per 100,000 person-years (95% CI). *Observed deaths. †P  0.05 and ‡P  0.001 for RR compared with male sex or Caucasian
race.
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suicides in this cohort occurred in Caucasian males.
Cause-speciﬁc mortality rates by diabetes diagnosis
cohort were censored at 30 years of follow-up for appro-
priate comparisons (Table 4). Overall, the 1965–1969 co-
hort had signiﬁcantly higher mortality rates from diabetes-
related causes compared with the 1975–1979 cohort (RR
1.5, P  0.05), which remained signiﬁcant after excluding
deaths not yet ﬁnalized by the MCC. Mortality rates from
non–diabetes-related causes were also higher for the
1965–1969 cohort, but this was not signiﬁcant (RR 1.7, P 
0.24). While cause-speciﬁc mortality rates for nearly all
diabetes complications were highest in the oldest cohort
(1965–1969) and tended to decrease stepwise to the young-
est cohort (1975–1979), none of the mortality rates differed
signiﬁcantly. In addition, further stratiﬁcation by diabetes
duration revealed that, compared with the 1965–1969
cohort, the 1975–1979 cohort had a signiﬁcantly lower
mortality rate over the ﬁrst 20 years’ duration of type 1
diabetes (RR 0.45, P  0.01) (data not shown).
Cause-speciﬁc standardized mortality ratios. Cause-
speciﬁc SMRs for this cohort were calculated (Table 5).
SMRs for acute complications were not calculated, since
these causes of death (hyperglycemia and diabetic keto-
acidosis) occur almost exclusively in individuals with type
1 diabetes. Overall, deaths from CVD (SMR 12.9, 95% CI
10.4–15.5), renal disease (104.3, 70.7–137.9), and infection
(41.2, 29.3–53.1) all occur at tremendously higher rates
than those seen in the comparable local population. How-
ever, deaths from non–diabetes-related causes such as
accident/suicide (SMR  1.2, 0.6–1.8) or cancer (SMR 
1.2, 0.5–2.0) occur at similar rates in type 1 diabetes to the
age-, sex-, and race-matched general population.
CVD, renal, and infection SMRs for females in this type
1 diabetes cohort were higher than the respective SMRs
for males (3 times higher for CVD and 2.5 times higher for
infection), whereas no dramatic differences in SMR were
seen by race or by diabetes diagnosis cohort for any cause
of death (Table 5).
Contribution of major diabetes complications to
death in type 1 diabetes. Finally, most deaths (65.0%) in
this type 1 diabetes cohort had at least one contributing or
secondary cause of death. Therefore, to determine the true
contribution of each major diabetes complication (acute
complications, renal disease, and cardiovascular disease)
in the deaths of individuals with type 1 diabetes, each
major complication was considered to contribute to a
death if it was either the underlying cause of death or a
secondary cause of death. For example, an individual
develops sepsis in the hospital after a bypass surgery
because of a nosocomial infection of a dialysis port. The
underlying cause of death might be classiﬁed as infection;
however, both renal and cardiovascular disease played
signiﬁcant secondary roles in this death.
The proportion of deaths to which each major diabetes
complication contributed is plotted by diabetes duration in
Fig. 2. Of note, at least one of these three major diabetes
complications contributed to 82.5% (n  231) of all deaths
in this cohort. Acute complications contributed to 80% of
all deaths within the ﬁrst 10 year of type 1 diabetes, but
then dropped to 20% of all deaths thereafter (Fig. 2A).
Renal disease does not contribute to any deaths until after
TABLE 4
Cause-speciﬁc mortality rates by year of diabetes diagnosis and duration of diabetes censored at 30 years of follow-up
n*
Diagnosis cohort
1965–1969 (n  79) 1970–1974 (n  74) 1975–1979 (n  49)
Diabetes-related 171 668.7 (507.4–830.1) 575.7 (433.5–717.8) 454.9 (317.3–592.5)†
Acute complication 38 152.0 (75.1–228.9) 155.3 (81.5–229.2) 65.0 (13.0–117.0)
Renal disease 26 121.6 (52.8–190.4) 64.0 (16.6–111.4) 75.8 (19.6–132.0)
CVD 67 263.4 (162.2–364.7) 219.3 (131.6–307.0) 184.1 (96.6–271.6)
Infection/other 40 131.7 (60.1–203.3) 137.1 (67.7–206.4) 130.0 (56.4–203.5)
Non–diabetes-related 31 131.7 (60.1–203.3) 100.5 (41.1–159.9) 75.8 (19.6–132.0)
Accident/violent 14 40.5 (0.8–80.2) 54.8 (11.0–98.7) 43.3 (0.9–85.8)
Cancer 7 40.5 (0.8–80.2) 9.1 (0.0–27.1) 21.7 (0.0–51.7)
Other 10 50.7 (6.3–95.1) 36.6 (0.7–72.4) 10.8 (0.0–32.1)
Overall 202 800.5 (624.0–977.0) 676.2 (522.1–830.2) 530.7 (382.1–679.3)†
Data are n or per 100,000 person-years (95% CI). *Observed deaths. †P  0.05 for RR of 1975–1979 compared with 1965–1969.
TABLE 5
Cause-speciﬁc standardized mortality ratios by sex, race, and diabetes diagnosis cohort
n* CVD Renal Infection Violent† Cancer
Sex
Male 138 8.8 (6.3–11.2) 77.8 (39.7–116.0) 28.1 (16.1–40.1) 1.4 (0.7–2.1) 1.2 (0.1–2.2)
Female 141 24.7 (17.9–31.6) 140.8 (80.6–201.1) 67.8 (41.2–94.4) 0.7 (0.0–1.6) 1.4 (0.2–2.5)
Race
Caucasian 239 12.4 (9.8–15.0) 103.7 (65.3–142.1) 45.0 (31.1–59.0) 1.5 (0.7–2.2) 1.3 (0.5–2.2)
African American 40 19.4 (8.4–30.3) 106.3 (36.9–175.8) 26.2 (5.2–47.2) — —
Diagnosis cohort
1965–1969 132 13.9 (10.0–17.7) 137.7 (77.4–198.1) 45.9 (25.8–66.1) 1.1 (0.1–2.1) 1.6 (0.3–2.8)
1970–1974 92 10.9 (7.0–14.8) 80.1 (30.5–129.7) 39.7 (20.2–59.2) 1.2 (0.2–2.2) 0.7 (0.0–1.8)
1975–1979 55 14.7 (8.3–21.2) 82.7 (21.4–144.0) 35.8 (13.6–58.0) 1.3 (0.2–2.5) 1.3 (0.0–3.2)
Overall 279 12.9 (10.4–15.5) 104.3 (70.7–137.9) 41.2 (29.3–53.1) 1.2 (0.6–1.8) 1.2 (0.5–2.0)
Data are n or cause-speciﬁc SMRs (95% CI). *Observed deaths. †Accident/suicide.
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about half of all deaths in this cohort (Fig. 2B). Cardiovas-
cular disease contributes to 10% of all deaths within the
ﬁrst 10 years of diabetes, but dramatically increases to
contribute to 60% of all deaths after 20 years of diabetes
(Fig. 2C). The role of renal disease in cardiovascular
deaths consistently increased with longer diabetes dura-
tion; renal disease contributed to 67% of all CVD deaths
before 20 years’ duration, but this contribution increases
to 85% of all CVD deaths after 30 years’ diabetes duration
(data not shown).
An exploratory analysis of the contribution of these
major complications by race, sex, or diabetes duration
revealed no signiﬁcant patterns, except that renal disease
contributed to more deaths in African Americans than in
Caucasians with type 1 diabetes (62.5 vs. 44.6%, respec-
tively; P  0.04).
DISCUSSION
These data represent the ﬁrst attempt to assess cause-
speciﬁc mortality in a population-based cohort with long-
standing (20 years) type 1 diabetes in the U.S. These
results clearly show that the higher mortality seen in type
1 diabetes compared with the general population results
almost exclusively from higher rates in diabetes-related
acute and chronic complications, since cause-speciﬁc
SMRs for cancer and for violent deaths do not differ from
the age-, sex-, and race-matched local population. Females
with type 1 diabetes had higher mortality rates for diabe-
tes-related causes, but males had higher mortality rates for
non–diabetes-related causes (especially violent deaths).
African Americans with type 1 diabetes have signiﬁcantly
higher mortality rates for all major diabetes-related causes
compared with Caucasians. Conversely, no African Amer-
icans died of non–diabetes-related causes in this type 1
diabetes cohort.
Causes of early mortality (10 years’ diabetes duration)
have been extensively studied in type 1 diabetes across
many countries and cohorts. An early report from the
Children’s Hospital of Pittsburgh cohort diagnosed be-
tween 1950 and 1980 reported 64% of all early deaths
(compared with 74% in our cohort) after diagnosis were
caused by acute complications (all diabetic ketoacidosis)
(21). An international study that included early mortality
data from the present study showed that acute complica-
tions (38%) were a leading cause of death in the ﬁrst 10
years of type 1 diabetes, followed by accident/suicide
(30%), with acute deaths occurring more commonly in
Japan and in Allegheny County than in Finland and Israel
(15). A more recent report on early mortality in type 1
diabetes from EURODIAB revealed that only 35% of deaths
in children diagnosed after 1989 (mean follow-up time 7.6
years) were due to acute diabetes complications (22), with
another 53% due to non-diabetes causes (accidents, sui-
cide, etc.).
Cause-speciﬁc mortality in longstanding type 1 diabetes
(20 years’ duration) has only been explored in a handful
of studies. Borch-Johnsen et al. (23) reported cause-
speciﬁc mortality ﬁndings for all individuals diagnosed
with type 1 diabetes (age 30) before 1943 at Steno
Memorial Hospital (Denmark) and followed until 1984.
More than 50% of deaths within 35 years of diabetes onset
were from renal disease, compared with only 5% of the
deaths after 40 years’ duration. For comparison, renal
disease was determined to be the underlying cause of
death in only 17% of individuals who died before 35 years’
diabetes duration in our cohort, suggesting that signiﬁcant
improvements in diabetes care between the 1940s and the
1970s have resulted in fewer renal deaths. However, on
closer examination, by including deaths where renal dis-
ease was a secondary cause of death, renal disease con-
tributed to 47% of all deaths in our cohort, indicating that
improvements in care have delayed but not drastically
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FIG. 2. Total contribution (underlying and/or secondary cause of
death) of major diabetes complications to deaths in type 1 diabetes.
Proportions of death in each diabetes duration interval where the
following complications either caused or contributed to death are
shown: acute complications (A), end-stage renal disease (ESRD) (B),
and CVD (C).
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A 2006 report from a national Norwegian childhood-
onset (age 15 years) type 1 diabetes cohort diagnosed
between 1973 and 1982 and followed until 2002 reported
ﬁndings dramatically different from the present report.
Notably, the Norwegian cohort had smaller proportions of
both CVD and infections than our cohort (15 vs. 35 and 5
vs. 16%, respectively), but larger proportions of both acute
complications and violent deaths (22 vs. 16 and 28 vs. 6%,
respectively) (11). While the authors did use a MCC to
determine the underlying cause of death, the contribution
of any secondary causes of death was not reported,
preventing a proper comparison of the contribution of
major complications between cohorts.
The cause-speciﬁc SMRs reported for diabetes-related
causes in our cohort are comparable to other reports
(10–12). All reports consistently show that SMRs for
diabetes-related causes are signiﬁcantly higher than the
respective general populations.
Little long-term follow-up of African Americans with
type 1 diabetes for cause-speciﬁc mortality exists outside
our cohort. We previously published data on the racial
differences in type 1 diabetes mortality combining the
present cohort with the Children’s Hospital of Pittsburgh
cohort (diagnosed 1965–1979) for a 20-year follow-up
analysis (24), where African Americans had a signiﬁcantly
higher risk of acute death (hazard ratio 4.9, 95% CI
2.0–11.6). These data are consistent with a retrospective
study of death certiﬁcates for Chicago residents (age 1–24
years) by Lipton et al. (25) that showed all eight (of 30 total
type 1 diabetes deaths) acute complication deaths at onset
occurred in either non-Hispanic black or Hispanic pa-
tients. Only two deaths occurred in white type 1 diabetic
patients during this interval in Chicago, and neither death
was due to acute complications.
We now report signiﬁcantly higher mortality rates for all
diabetes-related causes in African Americans compared
with Caucasians, which likely explains the dramatically
increased overall mortality rates in African Americans
with type 1 diabetes in our cohort (2,24,26). It should also
be noted that all of the deaths (excluding one unknown
cause of death) in African Americans in this cohort were
caused by either an acute or a chronic diabetes complica-
tion; however, these ﬁndings are based on a relatively
small number (n  40) of African American deaths. Young
African Americans have the highest violent death rates in
the U.S. (27,28), and based on our African American
follow-up time (2,161 person-years), we would expect to
see 2.5 deaths due to violent causes. However, none were
observed, suggesting that young African Americans with
type 1 diabetes are “protected” from violent deaths, but
are at a much higher risk of diabetes-related deaths than
their Caucasian counterparts. The poorer prognosis for
African Americans with type 1 diabetes might reﬂect an
underlying racial gap in socioeconomic status or access to
and use of health care present in the general U.S. popula-
tion (27). Regrettably, none of these known factors are
available for this cohort. A cause-speciﬁc analysis of
mortality in the New Jersey 725 (all African Americans
with type 1 diabetes) is forthcoming and should help
clarify these racial differences (29).
The contribution of major diabetes complications to
type 1 diabetes deaths has not been fully explored in a
large population-based cohort. Acute complications con-
tribute to 80% of all early (10 years’ duration) deaths, but
only contribute to 15% of deaths thereafter, consistent
with research showing that most early acute deaths in type
1 diabetes result from diabetic ketoacidosis (often at
diabetes onset or after an acute illness), whereas later
acute deaths tend to result from hypoglycemic episodes
(30,31). We also found that renal disease and CVD contrib-
ute to 50 and 60% of all deaths, respectively, after 20
years of type 1 diabetes duration. Although the incidence
of renal disease appears to be decreasing in the Pittsburgh
EDC study (13), the renal effects on cardiovascular disease
have yet to diminish in this cohort.
A key limitation of this study is that the cause-speciﬁc
early mortality rates may not be representative of the
current type 1 diabetes experience in the U.S., since study
participants have now had diabetes for 30 years, and
early diagnosis and treatment protocols have improved
tremendously since the 1960s and 1970s. In addition,
cause-speciﬁc analysis is limited to a few basic demo-
graphic variables (race, sex, and year of diagnosis), since
other socioeconomic and clinical variables were not ob-
tained at study inception (17). Finally, ﬁnalizing cause of
death in this cohort is an ongoing process. To date, 219
deaths (79%) have been ﬁnalized by the international MCC.
The remaining deaths have been classiﬁed based on the
death certiﬁcate and all additional information available to
date by an internal committee. However, a portion of these
deaths might be reclassiﬁed as we obtain additional infor-
mation regarding the circumstances surrounding each
death and each death becomes ﬁnalized by the MCC. As
such, sensitivity analyses were performed by excluding
nonﬁnalized deaths (n  60), and all comparisons except
for the racial difference in CVD deaths remained robust to
misclassiﬁcation.
These results offer the best picture of cause-speciﬁc
mortality in longstanding (28–43 years’ duration) type 1
diabetes in the U.S., since they come from a large (n 
1,075) population-based cohort with near complete ascer-
tainment (97%) of vital status. Also, we now have sufﬁcient
follow-up to determine sex, race, and temporal differences
in cause-speciﬁc mortality.
In summary, mortality rates for all diabetes-related
chronic complications show signs of decreasing, but all
remain signiﬁcantly higher than those seen in the age-,
sex-, and race-matched local general population. An em-
phasis on preventing acute complications early after diag-
nosis as well as preventing or delaying chronic diabetes
complications would likely result in major improvements
in lifespan for individuals with type 1 diabetes.
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